Integration of CT-Based Measurements into Surveillance PET/CT in Patients with Diffuse Large B Cell Lymphoma
| Autor: | Noa, Lavi, Gali, Shapira, Ariel, Zilberlicht, Noam, Benyamini, Dan, Farbstein, Eldad J, Dann, Rachel, Bar-Shalom, Irit, Avivi |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Aged 80 and over Male Remission Induction Middle Aged Antibodies Monoclonal Murine-Derived Young Adult Doxorubicin Fluorodeoxyglucose F18 Predictive Value of Tests Recurrence Vincristine Positron Emission Tomography Computed Tomography Antineoplastic Combined Chemotherapy Protocols Multivariate Analysis Humans Prednisone Female Lymphoma Large B-Cell Diffuse Rituximab Cyclophosphamide Aged Retrospective Studies |
| Zdroj: | The Israel Medical Association journal : IMAJ. 18(7) |
| ISSN: | 1565-1088 |
| Popis: | Despite the lack of clinical studies supporting the use of routine surveillance FDG-positron emission tomography (PET) in patients with diffuse large B cell lymphoma (DLBCL) who achieved remission, many centers still use this strategy, especially in high risk patients. Surveillance FDG-PET computed tomography (CT) is associated with a high false positive (FP) rate in DLBCL patients.To investigate whether use of specific CT measurements could improve the positive predictive value (PPV) of surveillance FDG-PET/CT.This retrospective study included DLBCL patients treated with CHOP or R-CHOP who achieved complete remission and had at least one positive surveillance PET. CT-derived features of PET-positive sites, including long and short diameters and presence of calcification and fatty hilum within lymph nodes, were assessed. Relapse was confirmed by biopsy or consecutive imaging. The FP rate and PPV of surveillance PET evaluated with/without CT-derived measurements were compared.Seventy surveillance FDG-PET/CT scans performed in 53 patients were interpreted as positive for relapse. Of these studies 25 (36%) were defined as true-positive (TP) and 45 (64%) as FP. Multivariate analysis found long or short axis measuring ≥ 1.5 and ≥ 1.0 cm, respectively, in PET-positive sites, International Prognostic Index (IPI) ≥ 2, lack of prior rituximab therapy and FDG uptake in a previously involved site, to be independent predictors of true positive surveillance PET (odds ratio 5.4, 6.89, 6.6, 4.9, P0.05 for all).PPV of surveillance PET/CT may be improved by its use in selected high risk DLBCL patients and combined assessment of PET and CT findings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|